Upload
lamont
View
19
Download
0
Embed Size (px)
DESCRIPTION
Tuberculosis, HAART Use and Survival in THRio Cohort, Rio de Janeiro, Brazil. Saraceni V 1 , King B 2 , Pacheco AG 3 , Golub JE 2 , Cavalcante SC 1 , Moulton LH 2 , Moore RD 2 , Chaisson RE 2 , Durovni B 1 - PowerPoint PPT Presentation
Citation preview
Tuberculosis, HAART Use and Survival in THRio Cohort, Rio de Janeiro, Brazil
Saraceni V1, King B2, Pacheco AG3, Golub JE2, Cavalcante SC1, Moulton LH2, Moore RD2, Chaisson RE2, Durovni B1
1-Rio de Janeiro City Health Dept., Rio de Janeiro, Brazil; 2 – Johns Hopkins SM, CTBR, Bloomberg SPH, JH HIV Clinic, Baltimore, USA; 3 – DEMQS, Fiocruz, Rio de Janeiro, Brazil
Abstract MOAB0305
Background
• Questions remain concerning the best time to initiate
HAART after TB diagnosis
• THRio – Observational cohort study to assess impact of
TB screening and INH preventive therapy on TB incidence
• Universal access to HAART in Brazil
• High TB-burden scenario – common first HIV diagnosis
and leading cause of death in HIV patients1
1. Saraceni et al., IJTLD 2008;12:769
Objectives
• Compare survival after TB diagnosis in HIV-positive
subjects followed at 29 health units in Rio de Janeiro
• Comparisons:
– exposure to HAART vs. no HAART in the overall group
– among those who initiated HAART, timing of initiation of
ARV therapy:
• Early HAART (<60 days of TB therapy)
• Deferred HAART (61-180 days of TB therapy)
• Withheld HAART (> 180 days of TB therapy)
Methods
• Inclusion Criteria:
– First episode of TB diagnosed from 01 Sep 2003 to 30
Jun 2006
– HIV diagnosed either before or after TB
– Right censored at last note in chart or 31 Dec 2006
– Mortality data available through State surveillance
system up to 31 Dec 2006
• Statistical Analysis:
– Descriptive statistics
– Kaplan-Meier estimates
– Cox proportional hazards regression models
Results
• At time of this analysis:
– 15,426 HIV+ patients receiving care in Rio City clinics
– 963 (6%) new TB cases diagnosed from 01 Sep 2003 to 30 Jun
2006
– 632 (66%) patients were HAART-naive at time of TB diagnosis
– 459 (73%) started HAART in the follow-up period
– 85/632 TB patients (13%) died during follow up
Table 1 – Characteristics of subjects by survival status
Characteristics Died(n=85)
Survived(n=547)
p-value
Gender male 67% 66% 0.847
Age (median, years) 36 36 0.329
HIV Dx after TB Dx 27% 39% 0.031
CD4 – TB (median, IQ) 164 (84-310) 183 (82-332) 0.871
VL – TB (log-median, IQ)) 4.4 4.5 0.576
TB Tx completed 32% 81% <0.001
HAART exposure (%) 49% 76% < 0.001
Table 2 – Characteristics of subjects by exposure to HAART
Characteristics HAART(n=459)
No HAART(n=173)
p-value
Gender male 68% 60% 0.049
Age (mean, years) 36 36 0.755
HIV Dx after TB Dx 38% 36% 0.531
CD4 – TB (median,IQ)) 150 (69-280) 355 (168-548) < 0.001
VL – TB (log, median) 4.4 4.4 0.639
TB Tx completed 82% 55% < 0.001
Death (#) 9% (42) 25% (43) < 0.001
Table 3 – Characteristics of subjects by timing of exposure to HAART
Characteristics <= 60 days(n=165)
61-180 days(n=168)
> 180 days(n=126)
Gender male 70% 70% 64%
Age (mean, years) 35 37 36
HIV Dx after TB Dx 24% 38% 58%
CD4 – TB (median,IQ) 135 (57-241) 137 (71-280) 202 (97-316)
VL – TB (log, median) 3.7 4.7 4.7
TB Tx completed 78% 84% 85%
Death (#) 7% (11) 11% (19) 10% (12)
Table 4 – Time to HIV diagnosis after TB episode among those exposed to HAART
Time to HIV diagnosis after TB
Median time in days IQ range P-value
<=60 days 7 4 – 31
61-180 days 27 3 – 66 0.009
> 180 days 67 24 - 196 <0.001
Graph 1 – Kaplan-Meier: Survival After a TB diagnosis, by exposure to HAART
Log-rank test – p<.001
.7.8
.91
Pro
port
ion
Sur
vivi
ng
0 500 1000 1500Time in days
No Yes
HAART ExposureSurvival after a TB diagnosis
Graph 2 – Kaplan-Meier: Survival After a TB diagnosis, by completion of TB treatment
Log-rank test – p<.001
.4.6
.81
Pro
port
ion
Sur
vivi
ng
0 500 1000 1500Time in days
No Yes
By TB treatment completionSurvival after a TB diagnosis
Graph 3 – Kaplan-Meier: Survival After a TB diagnosis, by completion of TB treatment, of those who survived longer
than 180 days
Log-rank test – p<. 001
.5.6
.7.8
.91
Pro
port
ion
Sur
vivi
ng
0 500 1000 1500Time in days
No Yes
By TB treatment completionSurvival after a TB diagnosis
Graph 4– Kaplan-Meier: Survival After a TB diagnosis, by CD4 category
Log-rank test – p=.985
.8.8
5.9
.95
1P
ropo
rtio
n S
urvi
ving
0 500 1000 1500Time in days
< 200 >= 200
By CD4 categorySurvival after a TB diagnosis
Graph 5 – Kaplan-Meier: Survival After a TB diagnosis, by timing of TB and HIV diagnosis
Log-rank test – p=.018
.7.8
.91
Pro
port
ion
Sur
vivi
ng
0 500 1000 1500Time in days
HIV after TB HIV before TB
By HIV and TB diagnosisSurvival after a TB diagnosis
Graph 6 – Kaplan-Meier: Time to HAART: <=60, 61-180 or > 180 days after TB treatment started
Log-rank test – p=.306
.8.8
5.9
.95
1P
ropo
rtio
n S
urvi
ving
0 500 1000 1500Time in days
<= 60 d 61 - 180 d> 180 d
By timing to HAARTSurvival after a TB diagnosis
Table 5: Cox model – Univariate analysis, all cases
Covariates HR CI 95% p-value
Gender 0.97 0.61 – 1.52 0.882
Age (years) 1.00 0,98 – 1.03 0.765
CD4 (absolute) 1.00 0.99 – 1.00 0.717
CD4<200 0.96 0.52 – 1.77 0.895
Viral load (log) 1.22 0.99 – 1.52 0.068
HIV before TB 1.79 1.09 - 2.91 0.020
HAART exposure 0.30 0.20 – 0.47 <0.001
TB Tx completed 0.12 0.07 – 0.19 <0.001
Table 6: Final Cox model, all cases
Covariates aHR CI 95% p-value
HAART (Yes) 0.48 0.31 – 0.74 0.001
TB Tx completed 0.14 0.09 – 0.22 <0.001
Conclusions
• HAART exposure significantly related to improved
survival after TB diagnosis (univariate HR=0.30;
aHR=0.48)
• The benefits of HAART were found despite lower median
CD4 counts in those who received it vs. those who did not
• Time of initiation of HAART not associated with
significant changes in survival
• Delays in diagnosis HIV in TB patients associated with
lower likelihood of receiving HAART
– Universal opt-out testing for all TB patients essential